Diagnosis Of Active Pulmonary Tuberculosis Research Articles

Carbon 13 urea breath test as a novel technique in the diagnosis of pulmonary tuberculosis

BackgroundThe Urea Breath Test (UBT) is the golden standard of investigation for Helicobacter pylori. Tuberculosis is common and endemic in Iraq, with limited investigations. This study was conducted to determine the safety and importance of UBT as a method for the diagnosis of active pulmonary tuberculosis. Material and methodA prospective, case-control study trial was conducted to determine the safety of 75 mg of inhaled C13-urea in 50 healthy participants. Then, in national TB, Over the course of a one-year study at a medical city in Baghdad, 50 participants with confirmed active pulmonary tuberculosis were enrolled. The safety of inhaled C13-urea was assessed by physical examination and spirometry. The C13-urea was administered by using a jet nebulizer, followed by the collection of exhaled breath at 15 and 30 min’ post-inhalation. A double-beam infrared spectrophotometer examined the isotopic ratio of (C13) CO2 to (C12) CO2. ResultsThe lung function test, which included forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1), did not show any changes that were clinically significant when healthy people and people with pulmonary tuberculosis (PTB) were compared to their baseline values. Additionally, there was no recorded incidence of adverse events among both healthy individuals and those with pulmonary tuberculosis (PTB). After 15 min of the nebulization process, the delta over baseline (DOB) means of the control group and PTB patients were −1.2381 ± 1.8392 and 4.8215 ± 5.1889, respectively. After 15 min of the nebulization process, the DOB means of the control group and PTB patients were −1.9628 ± 3.0717 and 3.5686 ± 3.8484, respectively. ConclusionInhaling 13 C-urea seemed safe. DOB values in PTB patients were greater than in controls. Preliminary data suggest that DOB values at 15 min were higher than 30 min. This has potential for diagnosing Mycobacterium tuberculosis.

Detection of Mycobacterium tuberculosis Complex in Sputum Samples Using Droplet Digital PCR Targeting mpt64.

Tuberculosis (TB) is one of the top 10 causes of death worldwide. It is challenging to find methods of diagnosis of active pulmonary TB that are sensitive enough to detect cases for proper treatment before unintentional transmission. Droplet digital PCR (ddPCR) is a highly sensitive method to detect genetic material of pathogens, but it has rarely been used for diagnosis of TB. This study compared the sensitivity of ddPCR with that of GeneXpert and AFB smear microscopy in 180 leftover sputum samples from patients suspected of having TB on the basis of clinical symptoms and radiography. Absolute quantification of copy numbers of MTB-specific genes was possible using ddPCR targeting the mpt64 gene. Among the 180 samples, 41.1% were diagnosed as having TB using ddPCR. The sensitivities of AFB smear microscopy, GeneXpert and ddPCR were 41.9%, 82.4% and 100%, respectively. AFB smear microscopy and GeneXpert both had a specificity of 100%, and the specificity of ddPCR was 95.3%. The accuracy of ddPCR (97.2%) is higher than that of GeneXpert (92.7%). This robust ddPCR system could potentially be used as a method for early diagnosis of TB.

Deep learning based CT images automatic analysis model for active/non-active pulmonary tuberculosis differential diagnosis.

Active pulmonary tuberculosis (ATB), which is more infectious and has a higher mortality rate compared with non-active pulmonary tuberculosis (non-ATB), needs to be diagnosed accurately and timely to prevent the tuberculosis from spreading and causing deaths. However, traditional differential diagnosis methods of active pulmonary tuberculosis involve bacteriological testing, sputum culturing and radiological images reading, which is time consuming and labour intensive. Therefore, an artificial intelligence model for ATB differential diagnosis would offer great assistance in clinical practice. In this study, computer tomography (CT) scans images and corresponding clinical information of 1160 ATB patients and 1131 patients with non-ATB were collected and divided into training, validation, and testing sets. A 3-dimension (3D) Nested UNet model was utilized to delineate lung field regions in the CT images, and three different pre-trained deep learning models including 3D VGG-16, 3D EfficientNet and 3D ResNet-50 were used for classification and differential diagnosis task. We also collected an external testing set with 100 ATB cases and 100 Non-ATB cases for further validation of the model. In the internal and external testing set, the 3D ResNet-50 model outperformed other models, reaching an AUC of 0.961 and 0.946, respectively. The 3D ResNet-50 model reached even higher levels of diagnostic accuracy than experienced radiologists, while the CT images reading and diagnosing speed was 10 times faster than human experts. The model was also capable of visualizing clinician interpretable lung lesion regions important for differential diagnosis, making it a powerful tool assisting ATB diagnosis. In conclusion, we developed an auxiliary tool to differentiate active and non-active pulmonary tuberculosis, which would have broad prospects in the bedside.

MtTB: A Web-Based R/Shiny App for Pulmonary Tuberculosis Screening.

Pulmonary tuberculosis caused by Mycobacterium tuberculosis remains a global issue. However, the diagnosis of active pulmonary tuberculosis (TB) remains a challenge in the clinic. Small non-coding RNAs are potential diagnostic biomarkers for pulmonary tuberculosis. However, the current normalization methods are not stable and usually fail to reliably detect differentially expressed sncRNAs. To identify reliable biomarkers for pulmonary tuberculosis screening, we utilized the ratio-based method on the newly discovered mitochondria-derived small RNAs in human peripheral blood mononuclear cells. The prediction model of seven mtRNA biomarkers noteworthily enables the discrimination between pulmonary tuberculosis patients and controls in discovery (AUC = 0.906, 23 patients) and independent validation cohort (AUC = 0.968, 20 patients). Moreover, we present mtTB (https://tuberculosis.shinyapps.io/mtTB/), a novel R Graphical User Interface (GUI) that provides reliable biomarkers for the feasibility of blood-based screening, and produce a more accurate tool for pulmonary tuberculosis diagnosis in real clinical practice.

Diagnosis of Active Pulmonary Tuberculosis and Community Acquired Pneumonia Using Convolution Neural Network Based on Transfer Learning

A convolutional neural network (CNN) model for the diagnosis of active pulmonary tuberculosis (APTB) and community-acquired pneumonia (CAP) using chest radiographs (CRs) was constructed and verified based on transfer learning. CRs of 1247 APTB cases, 1488 CAP cases and 1247 normal cases were collected. All CRs were randomly divided into training set (1992 cases), validation set (1194 cases) and test set (796 cases) by stratified sampling in 5:3:2 radio. After normalization of CRs, the convolution base of pre-trained CNN (VGG16) model on ImageNet dataset was used to extract features, and the grid search was used to determine the optimal classifier module, which was added to the convolution base for transfer learning. After the training, the model with the highest accuracy of the validation set was selected as the optimal model to verify in the test set and calculate the accuracy of the model. The accuracy of validation set in the 63rd epochs was the highest, which was 0.9430, and the corresponding Categorical crossentropy was 0.1742. The accuracy of the training set was 0.9428, and the Categorical crossentropy was 0.1545. When the optimal model was applied to the test set, the accuracy was 0.9447, and the Categorical crossentropy was 0.1929. The transfer learning-based CNN model has good classification performance in the diagnosis of APTB, CAP and normal patients using CRs.

Intestinal and perianal tuberculosis: an uncommon clinical presentation and challenging diagnosis.

We present the case of a 40-year-old immunocompetent man with complaints of perianal abscess, diarrhea, and weight loss for 3 months. He denied respiratory symptoms. Colonoscopy revealed ulcers and histopathology showed non-necrotizing granulomas and excluded acid-fast bacilli. Initially, the clinical and histological findings favored the diagnosis of Crohn's disease, however, further investigation by performing chest radiography in the context of a pre-immunomodulatory checklist, revealed pulmonary cavitations confirmed on computed tomography scan. Further mycobacteriological studies suggested the diagnosis of active pulmonary tuberculosis. Demonstration of the presence of Mycobacterium tuberculosis in the colon was possible by RT-PCR. Complete resolution of intestinal and perianal symptoms was achieved 2 weeks after treatment with anti-bacillary agents.

Quantitative Rapid Test for Detection and Monitoring of Active Pulmonary Tuberculosis in Nonhuman Primates.

Simple SummaryTuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is the most lethal infectious disease from a single pathogen for which there is no effective vaccine available. Rhesus macaques are extremely susceptible to MTB and therefore represent relevant models to study the pathogenesis of TB and assess the potential of TB drugs and vaccines. However, there are no diagnostic tools currently available that allow rapid, user-friendly detection of TB for either TB research purposes or monitoring nonhuman primate colonies. To develop a rapid diagnostic test, we investigated whether low complexity lateral flow assays (LFAs) that we recently developed for rapid and quantitative detection of human serum proteins are applicable to detect and monitor active pulmonary TB in NHPs. We found that serum levels of SAA1, IP-10, and IL-6 detected by LFAs were significantly increased after MTB infection in rhesus macaques. Moreover, levels of these biomarkers correlated with disease severity as determined by pathology scoring and allowed detection of the effect of vaccination and drug treatment in experimentally MTB infected macaques. These UCP-LFAs thus offer a low-cost, convenient, and minimally invasive diagnostic tool that can be used to assess new therapeutic and prophylactic treatment methods in macaques to tackle TB.Nonhuman primates (NHPs) are relevant models to study the pathogenesis of tuberculosis (TB) and evaluate the potential of TB therapies, but rapid tools allowing diagnosis of active pulmonary TB in NHPs are lacking. This study investigates whether low complexity lateral flow assays utilizing upconverting reporter particles (UCP-LFAs) developed for rapid detection of human serum proteins can be applied to detect and monitor active pulmonary TB in NHPs. UCP-LFAs were used to assess serum proteins levels and changes in relation to the MTB challenge dosage, lung pathology, treatment, and disease outcome in experimentally MTB-infected macaques. Serum levels of SAA1, IP-10, and IL-6 showed a significant increase after MTB infection in rhesus macaques and correlated with disease severity as determined by pathology scoring. Moreover, these biomarkers could sensitively detect the reduction of bacterial levels in the lungs of macaques due to BCG vaccination or drug treatment. Quantitative measurements by rapid UCP-LFAs specific for SAA1, IP-10, and IL-6 in serum can be utilized to detect active progressive pulmonary TB in macaques. The UCP-LFAs thus offer a low-cost, convenient, and minimally invasive diagnostic tool that can be applied in studies on TB vaccine and drug development involving macaques.

Delayed diagnosis of active pulmonary tuberculosis - potential risk factors for patient and healthcare delays in Portugal

BackgroundEarly diagnosis and treatment of pulmonary tuberculosis (PTB) is essential for an effective control of the tuberculosis (TB) epidemic. Delayed diagnosis and treatment of TB increases the chance of complications and mortality for the patients, and enhances TB transmission in the population. Therefore, the aim of this study was to characterize patient, healthcare and total delay in diagnosing PTB and assess the effect of clinical and sociodemographic factors on the time until first contact with healthcare or reaching a PTB diagnosis.MethodsRetrospective cohort study that included active PTB patients notified in the National Tuberculosis Surveillance System (SVIG-TB), between 2008 and 2017. Descriptive statistics, Kaplan-Meier estimates, logrank test and Cox proportional hazards model were used to characterize patient, healthcare and total delay and estimate the effect of clinical and sociodemographic variables on these delays. Significance level was set at 0.05.ResultsMedian patient, healthcare and total delays was 37 days (Interquartile range (IQR): 19–71), 8 days (IQR: 1–32) and 62 days (IQR: 38–102), respectively.The median patient delay showed a constant increase, from 33 days in 2008 to 44 days in 2017. The median total delay presented a similar trend, increasing from 59 days in 2008 to 70 days in 2017. Healthcare delay remained constant during the study period. More than half of the PTB cases (82.9%) had a delay > 1 month between symptom onset and diagnosis.In the final Cox model, alcohol abuse, unemployment and being from a high TB incidence country were factors significantly associated with longer patient delay, while being female, having more than 45 years, oncologic and respiratory diseases were associated with longer healthcare delay. Being female, having more than 45 years and being from a high TB incidence country were associated with longer total delay.ConclusionsPatient delay and total delay have increased in recent years. Older patients, patients with alcohol problems, other comorbidities, unemployed or from countries with high TB incidence would benefit from the development of specific public health strategies that could help reduce the delay in TB diagnosis observed in our study.This study emphasizes the need to promote awareness of TB in the general population and among the healthcare community, especially at ambulatory care level, in order to reduce the gap between beginning of symptoms and TB diagnosis.

A SYSTEMIC REVIEW ON TUBERCULOSIS: DIAGNOSIS, TREATMENT AND CHALLENGES

In developed countries worldwide, tuberculosis is an endemic condition. The early and conclusive diagnosis of Active Pulmonary Tuberculosis (TB) is important for avoiding death and spreading disease, both at the person and population level. Diagnostics commonly available can be widely divided into techniques focused on microscopy, culture, and molecular methods. The Nucleic Acid Amplification Test (NAA), Line Probe Assay, and Cartridge Based Nucleic Acid Amplification Test (CB NAAT) are three advanced molecular approaches that are listed. All these diagnostic strategies, however, either have weakened sensitivity or require costly instruments that eventually restrict their usefulness as a proven form of diagnosis. Sputum microscopy, which detects Mycobacterium tuberculosis (Mtb) in a clinical sample, is currently used as an easy and inexpensive diagnostic test for TB. The sub-optimal sensitivity of this test is based first on the abundance of Mtb in the sample and secondly on the accuracy of the operator. Culture-based diagnostic studies, on the other hand, are time intensive and reliant on knowledge and infrastructure. Likewise, molecular experiments often rely on expensive instrumentation and complexity in scientific visualization. An easy, sensitive and inexpensive diagnostic approach for early-stage Active Pulmonary Tuberculosis diagnosis is therefore still a primary requirement.

Past and Present Approaches to Diagnosis of Active Pulmonary Tuberculosis.

Tuberculosis disease continues to contribute to the mortality burden globally. Due to the several shortcomings of the available diagnostic methods, tuberculosis disease continues to spread. The difficulty to obtain sputum among the very ill patients and the children also affects the quick diagnosis of tuberculosis disease. These challenges warrant investigating different sample types that can provide results in a short time. Highlighted in this review are the approved pulmonary tuberculosis diagnostic methods and ongoing research to improve its diagnosis. We used the PRISMA guidelines for systematic reviews to search for studies that met the selection criteria for this review. In this review we found out that enormous biosignature research is ongoing to identify host biomarkers that can be used as predictors of active PTB disease. On top of this, more research was also being done to improve already existing diagnostic tests. Host markers required more optimization for use in different settings given their varying sensitivity and specificity in PTB endemic and non-endemic settings.

Association of Urinary Interferon Gamma Protein-10 Levels and Low Levels of Cluster of Differentiation 4 Serum in Patients with Tuberculosis-Human Immunodeficiency Virus Coinfection

BACKGROUND: Tuberculosis (TB) infection caused by Mycobacterium tuberculosis was the most frequent opportunistic infection in human immunodeficiency virus (HIV) patients that lead to increasing of morbidity and mortality. Very low cluster of differentiation 4 (CD4) levels causing problem in TB/HIV diagnostic because unspecific clinical manifestation. Urine interferon gamma protein-10 (IP10) examination is a method that is relatively easier and safer to do, so it can be used as an alternative method in establishing the diagnosis TB/HIV. AIM: The aim of this study was to investigate the association between urinary IP-10 and level of CD4 serum in patients with TB/HIV coinfection. MATERIALS AND METHODS: This study was conducted at the Department of Internal Medicine, Faculty of Medicine, Dr. M. Djamil Hospital, Padang, Indonesia, involved 30 patients with active TB/HIV coinfection whose urine and blood serum were collected to evaluate IP-10 and CD4 level. RESULTS: There is a significant relationship between urine IP10 levels as a biomarker for the diagnosis of active pulmonary TB in HIV patients and serum CD4 levels in TB-HIV coinfected patients with moderate correlation strength. CONCLUSION: Further research is needed with a larger sample size to see the effect of low serum CD4 levels on the sensitivity of urine IP10 diagnosis.

Factors associated with differential T cell responses to antigens ESAT-6 and CFP-10 in pulmonary tuberculosis patients.

The T-SPOT.TB assay detects cellular immune responses to 2 core Mycobacterium tuberculosis antigens, early secreted antigenic target of 6-kDa protein (ESAT-6) and culture filtrate protein-10 (CFP-10). T-SPOT.TB has been recently used for auxiliary diagnosis of active pulmonary tuberculosis (PTB). However, testing can produce inconsistent results due to differential PTB patient immune responses to these antigens, prompting us to identify factors underlying inconsistent results.Data were retrospectively analyzed from 1225 confirmed PTB patients who underwent T-SPOT.TB testing at 5 specialized tuberculosis hospitals in China between December 2012 and November 2015. Numbers of spot-forming cells (SFCs) reflecting T cell responses to ESAT-6 and CFP-10 antigens were recorded then analyzed via multivariable logistic regression to reveal factors underlying discordant T cell responses to these antigens.The agreement rate of 84.98% (82.85%–86.94%) between PTB patient ESAT-6 and CFP-10 responses demonstrated high concordance. Additionally, positivity rates were higher for ESAT-6 than for CFP-10 (84.8% vs 80.7%, P < .001), with ESAT-6 and CFP-10 microwell SFC numbers for each single positive group not differing significantly (P > .99), while spot numbers of the single positive group were lower than numbers for the double positive group (P < .001). Elderly patients (aged ≥66 years) and patients receiving retreatment were most likely to have discordance results.ESAT-6 promoted significantly more positive T-SPOT.TB results than did CFP-10 in PTB patients. Advanced age and retreatment status were correlated with discordant ESAT-6 and CFP-10 results. Assessment of factors underlying discordance may lead to improved PTB diagnosis using T-SPOT.TB.

Identification of potential lipid biomarkers for active pulmonary tuberculosis using ultra-high-performance liquid chromatography-tandem mass spectrometry.

Early diagnosis of active pulmonary tuberculosis (TB) is the key to controlling the disease. Host lipids are nutrient sources for the metabolism of Mycobacterium tuberculosis. In this research work, we used ultra-high-performance liquid chromatography-tandem mass spectrometry to screen plasma lipids in TB patients, lung cancer patients, community-acquired pneumonia patients, and normal healthy controls. Principal component analysis, orthogonal partial least squares discriminant analysis, and K-means clustering algorithm analysis were used to identify lipids with differential abundance. A total of 22 differential lipids were filtered out among all subjects. The plasma phospholipid levels were decreased, while the cholesterol ester levels were increased in patients with TB. We speculate that the infection of M. tuberculosis may regulate the lipid metabolism of TB patients and may promote host-assisted bacterial degradation of phospholipids and accumulation of cholesterol esters. This may be related to the formation of lung cavities with caseous necrosis. The results of receiver operating characteristic curve analysis revealed four lipids such as phosphatidylcholine (PC, 12:0/22:2), PC (16:0/18:2), cholesteryl ester (20:3), and sphingomyelin (d18:0/18:1) as potential biomarkers for early diagnosis of TB. The diagnostic model was fitted by using logistic regression analysis and combining the above four lipids with a sensitivity of 92.9%, a specificity of 82.4%, and the area under the curve (AUC) value of 0.934 (95% CI 0.873 - 0.971). The machine learning method (10-fold cross-validation) demonstrated that the model had good accuracy (0.908 AUC, 85.3% sensitivity, and 85.9% specificity). The lipids identified in this study may serve as novel biomarkers in TB diagnosis. Our research may pave the foundation for understanding the pathogenesis of TB.

MicroRNA-155 from sputum as noninvasive biomarker for diagnosis of active pulmonary tuberculosis.

Objective(s):Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a widespread infectious disease around the world. Early diagnosis is always important in order to avoid spreading. At present, many studies have confirmed that microRNA (miRNA) could be a useful tool for diagnosis. This study aimed to evaluate whether miRNAs could be regarded as a noninvasive diagnosis biomarker from sputum for pulmonary tuberculosis (PTB).Materials and Methods:The M. tuberculosis strain H37Rv was incubated and cultured with human macrophage line THP-1. The total RNA was extracted from the THP-1 cells for detection. Six increased expressions of miRNAs were selected by miRNA microarray chips and the miRNAs were confirmed by qRT-PCR in the M. tuberculosis infection cell model. At last, the efficiency of other methods was compared with using miRNA.Results:Only miR-155 showed a better diagnostic value for PTB than the other five miRNAs to distinguish PTB from non-PTB, including pneumonia, lung cancer, and unexplained pulmonary nodules. Next, we detected and analyzed the results of 68 PTB patients and 122 non-PTB, the sensitivity and specificity of miR-155 detection was 94.1% and 87.7%, respectively. It was higher than sputum smear detection and anti-TB antibody detection. But slightly lower than ELISpot (97%, P=0.404). Interestingly, the ranking of sputum smear by Ziehl-Neelsen staining had positive correlation with the expression level of miR-155 in smear-positive sputum (R2=0.8443, P<0.05).Conclusion:Our research suggested that miR-155 may be an efficiency biomarker for active PTB diagnosis and bacteria-loads evaluation.

Tuberculosis and its Diagnosis: Past, Present and Future

Tuberculosis is an endemic disease in the developing countries worldwide. Early and definitive diagnosis of Active Pulmonary Tuberculosis (TB) is important both at individual and population level for reducing mortality as well as transmission of the disease. Currently available diagnostics can be broadly categorized into microscopy, culture based and molecular method-based approaches. Among the advanced molecular methods, the Nucleic Acid Amplification Test (NAA), Line Probe Assay and Cartridge Based Nucleic Acid Amplification Test (CB NAAT) are mentionable. However, all these diagnostic methods either have compromised sensitivity or require expensive instrumentations that ultimately limit their efficacy as established diagnostic method. Currently used rapid and affordable diagnostic test for TB is sputum microscopy that detects Mycobacterium tuberculosis (Mtb) in clinical sample. This test has sub-optimal sensitivity as it depends firstly on the abundance of Mtb in the sample and secondly on operator’s accuracy. On the other hand, culture-based diagnostic tests are time-consuming and dependent on expertise and infrastructure. Likewise, molecular tests are also dependent on expensive instrumentation and technical sophistication. Hence, rapid, sensitive and affordable diagnostic method for the detection of Active Pulmonary tuberculosis at an early phase is still a primary requisite.

Is COVID-19 masking or delayed the diagnosis of active pulmonary tuberculosis? A case report from Bangladesh

Background: The pandemic COVID-19 impacts a major global health crisis in the whole world including Bangladesh. Bangladesh is one of the world’s high tuberculosis (TB) burden countries and TB is a major public health concern in the country. It also observed that respiratory disease presented with similar features of coronavirus disease, unfortunately and regrettably overlooked by the physicians worldwide due to the pandemic crisis. We presented a case of pulmonary tuberculosis and coronavirus disease (COVID-19) co-infection which has not been reported much.Case report: A 55 years old female presented with acute respiratory symptoms superimposed on chronic respiratory symptoms as she was suffering from bronchial asthma, diagnosed with severe pneumonia. Oropharyngeal and nasal swab sample were found positive for coronavirus by RT-PCR assay. Assessments of the previous history and clinical scenario also suggested investigation for tuberculosis and finding positive of Sputum for acid fast bacilli (AFB) and Gene X pert detected Mycobacterium tuberculosis complex with rifampicin sensitivity. Patient was treated concomitantly for COVID-19 pneumonia and starting anti-tubercular drugs. So physicians should suspect COVID-19 co infections with pulmonary tuberculosis while treating the patient presented with respiratory and systemic features .It should keep in consideration for early diagnosis of Pulmonary tuberculosis to reduce the morbidity and mortality of the patients and to prevent transmission in the community from active sputum positive pulmonary tuberculosis.

Characterization of antibody response against 16kD and 38kD of M. tuberculosis in the assisted diagnosis of active pulmonary tuberculosis.

BackgroundIn view of the inability of traditional etiological methods to diagnose pulmonary tuberculosis rapidly and effectively, the antibody responses against 38kD and 16kD-antigens of Mycobacterium tuberculosis (M. tuberculosis) were both detected in order to obtain a better serological detection method for M. tuberculosis.MethodsM. tuberculosis-secreted protein 38kD and membrane protein 16kD were prokaryotically expressed and purified, and then used as detection antigens. A novel evolved immunoglobulin-binding molecule (NEIBM)-ELISA method was used to detect antibody levels against 38kD and 16kD in active tuberculosis patients (confirmed tuberculosis cases and clinically diagnosed cases), to explore the significance of these two antigens in serological detection of M. tuberculosis, and to study the diagnostic value of the combined detection of the two antigens in active pulmonary tuberculosis.ResultsThe results showed that the positive detection rates of the 16kD antigen and 38kD antigen of M. tuberculosis were higher (about 44%) in the confirmed cases of tuberculosis, and there was no significant difference in the positive detection rates of the two antigens (P=0.786). The combined detection of these two antigens showed that the positive detection rate could be increased to 61.5%, which was significantly better than the detection effect of the two antigens alone. The positive detection rates of 16kD and 38kD antigens were 26–30% in clinically diagnosed tuberculosis cases, which were lower than those in confirmed tuberculosis cases, and there was no significant difference in the positive detection rates of the two antigens (P=0.242). The detection effect of the two combined antigens was better than that of the 16kD and 38kD antigens alone, but the detection rate was still lower than that of the confirmed tuberculosis cases.ConclusionsThis study found that the detection effect of 16kD and 38kD antigens was similar in confirmed cases and clinically diagnosed cases of pulmonary tuberculosis, and that the detection effect needs to be further improved. The combined detection of the two antigens showed a significantly better detection effect than the two antigens alone, suggesting that the combined detection of multiple antigens can be used for serological diagnosis of M. tuberculosis infection in clinic.

Delayed Isolation of Active Pulmonary Tuberculosis in Hospitalized Patients: A Pivotal Role of Radiologic Evaluation.

OBJECTIVE. The purpose of this study was to determine factors related to delayed isolation of patients hospitalized with active pulmonary tuberculosis (TB). MATERIALS AND METHODS. A total of 130 immunocompetent hospitalized patients with active pulmonary TB who had positive sputum culture results from January 2015 to December 2017 were reviewed. Delayed isolation of pulmonary TB was defined as failure to initiate airborne isolation within the first 3 days of hospitalization. Clinical and microbiologic characteristics of the patients and radiologic features on chest radiography (n = 130) and chest CT (n = 118) were retrospectively reviewed. Findings were compared between patients with early isolation and those with delayed isolation. Univariate and multivariate analyses were performed to determine independent predictors of delayed isolation. RESULTS. Forty-four patients (34%) had delayed isolation after initial hospitalization. On univariate and multivariate analyses, atypical presentation of active pulmonary TB on CT (odds ratio, 7.203; 95% CI, 2.203-23.551; p = 0.001) and concurrent lung parenchymal diseases on CT (odds ratio, 14.605; 95% CI, 3.274-65.155; p < 0.001) were significant predictors of delayed isolation of patients with active pulmonary TB. CONCLUSION. Awareness of the factors related to delayed diagnosis of active pulmonary TB is important to avoid an unexpected in-hospital outbreak of TB and control the disease. Atypical presentation of active pulmonary TB and concurrent lung parenchymal diseases on CT are significant factors related to delayed isolation of hospitalized patients with active pulmonary TB.

Effects of age on the association between pulmonary tuberculosis and lung cancer in a South Korean cohort.

BackgroundVarious studies have investigated the association between pulmonary tuberculosis (TB) and lung cancer However, how the relationship between TB and lung cancer may differ by age is not yet clear. This study investigated how risk for lung cancer after pulmonary TB may differ by age.MethodsThis study used the National Health Insurance Service–National Sample Cohort in South Korea. We compared 3,776 pulmonary TB patients with 18,880 controls matched for sex and age during the period from 2003 to 2013. We analyzed the incidence of lung cancer after diagnosis of active pulmonary TB. A multivariate Cox proportional hazard model was used to calculate the adjusted hazard ratio (HR) of lung cancer after adjusting for sex, age, house income, and smoking status.ResultsAmong 3,776 pulmonary TB patients, 86 had lung cancer diagnoses, whereas there were 108 lung cancer patients among 18,880 controls. The incidence rate ratio in the pulmonary TB group was 12.26 within 1 year and 3.33 at 1–3.9 years after TB infection, compared to the control group. There was increased risk for lung cancer in pulmonary TB patients compared to controls (HR, 4.18; 95% CI, 3.15–5.56). Compared to patients <50 years of age, the risks for lung cancer were HR 9.85, 7.1, 3.32, and 2.57 in patients aged 50–59, 60–69, and ≥70 years, respectively.ConclusionsPulmonary TB is a risk factor for lung cancer. Patients with pulmonary TB should be monitored for subsequent development of lung cancer, particularly in younger patients.

LEAVE NO LOBE UNSCOPED: A CASE OF MYCOBACTERIUM TB OF THE RIGHT MIDDLE LOBE

SESSION TITLE: Monday Medical Student/Resident Case Report Posters SESSION TYPE: Med Student/Res Case Rep Postr PRESENTED ON: 10/21/2019 02:30 PM - 03:15 PM INTRODUCTION: Tuberculosis (TB) is one of the top ten leading causes of death worldwide, now surpassing HIV/AIDS as the leading cause of death from infectious disease (1). Earlier detection significantly reduces mortality from tuberculosis, and the World Health Organization estimates that earlier diagnosis has averted 54 million deaths since the year 2000 (1). Assumptions that TB only presents in certain patterns often delays diagnosis to the detriment of the patient and those close to them (2). We describe an atypical presentation of TB presenting in the right middle lobe. CASE PRESENTATION: A 75 year-old Ecuadorian woman with a history of hypertension, diabetes, and emphysema presented to the hospital with hemoptysis and fevers. CT of the chest with contrast demonstrated a right middle lobe cavitary lesion, which was read as necrotizing pneumonia. Broad-spectrum antibiotics were initiated to treat pneumonia. However, due to the presentation, cavitary nature of the lesion, and the patient coming from a TB endemic region, a bronchoscopy was pursued. Acid-fast bacillus stains performed on the bronchoalveolar lavage were positive for mycobacterium tuberculosis, confirming the diagnosis of active pulmonary tuberculosis. RIPE treatment was initiated. The patient soon afterward developed massive hemoptysis requiring intubation and upgraded to the medical intensive care unit. IR-guided embolization of the right bronchial artery middle lobe segment resolved the bleed. She extubated shortly afterward and eventually discharged home on RIPE treatment. DISCUSSION: TB has recently surpassed HIV/AIDS as the leading cause of death from infectious disease (1). A major reason for this alarming statistic is that TB can manifest in so many different fashions, leading to delays in diagnosis (2). An increasing number of atypical manifestations of TB are being described in the literature, challenging traditional concepts of its presentation (2, 3). Classically, tuberculosis affects the upper lobes in immunocompetent hosts, which is believed to be due to the increased oxygen tension and decreased lymphatic drainage facilitating replication of the organism (3, 4). In immunocompromised hosts, it has been found to commonly affect the lower lobes, particularly the superior segments (5, 6). However in this patient, TB presented in the middle lobe, which has rarely been described (4). We present a case of TB affecting the middle lobe in the hopes of contributing to literature challenging traditional concepts about this lethal and evasive disease. CONCLUSIONS: TB typically presents in the upper lobes. Atypical presentations in other areas of the lung may lead to delayed or incorrect diagnosis. Patient factors such as medical conditions, demographics, and overall clinical picture should be considered in patients with cavitary lung disease. Presented is an atypical case of TB of the right middle lobe. Reference #1: World Health Organization. Global Tuberculosis Report 2018. Geneva, WHO, 2018. Reference #2: Restrepo et al. “Imaging manifestations of thoracic tuberculosis.” Radiologic Clinics of North America 2016; 54(3):453-473. Reference #3: Mathur M et al. “Radiological manifestations of pulmonary tuberculosis – a comparative study between immunocompromised and immunocompetent patients.” Journal of Clinical and Diagnostic Research 2017; 11(9):TC06-TC09. DISCLOSURES: No relevant relationships by Dawn Maldonado, source=Web Response Stock holder relationship with Eli Lilly Please note: $5001 - $20000 Added 03/26/2019 by Terence McGarry, source=Admin input, value=Dividends Stock holder relationship with Merek Please note: $5001 - $20000 Added 03/26/2019 by Terence McGarry, source=Admin input, value=Dividends No relevant relationships by Michael Megally, source=Web Response